Volume 7.18 | May 20

Prostate Cell News 7.18 May 20, 2016
Prostate Cell News
     In this issue: Publications | Reviews | Science News | Industry News | Policy News | Events | Jobs
Cell Therapy News on Facebook  PCN on Twitter
Differences in Metabolism between Androgen-Dependent and Castration Resistant Prostate Cancer May Lead to New Therapies
Researchers have determined that castration resistant prostate cancer has particular metabolic characteristics that may open new possibilities for treatment. [Press release from Baylor College of Medicine discussing online publication in Nature Communications] Press Release | Full Article
Learn More: Standardized Tools for Cancer Research
PUBLICATIONS (Ranked by impact factor of the journal)

Resistance to Docetaxel in Prostate Cancer Is Associated with Androgen Receptor Activation and Loss of KDM5D Expression
Investigators demonstrated that the prostate cancer cell lines LNCaP and LAPC4 display markedly different sensitivity to docetaxel with androgen receptor activation, and RNA-seq analysis of these cell lines identified KDM5D (lysine-specific demethylase 5D) encoded on the Y chromosome as a potential mediator of this sensitivity. [Proc Natl Acad Sci USA] Abstract

ERG Signaling in Prostate Cancer Is Driven through PRMT5-Dependent Methylation of the Androgen Receptor
From a screen for functionally relevant ERG interactors, the authors identified the arginine methyltransferase PRMT5. ERG recruits PRMT5 to androgen receptor (AR)-target genes, where PRMT5 methylates AR on arginine 761. [Elife] Full Article

p27T187A Knockin Identifies Skp2/Cks1 Pocket Inhibitors for Advanced Prostate Cancer
Scientists identified pRb and p53 doubly deficient (DKO) prostate tumorigenesis as a context in which p27 ubiquitination by SCFSkp2/Cks1 is required for p27 downregulation. p27 protein accumulated in prostate when p27T187A KI mice underwent DKO prostate tumorigenesis. [Oncogene] Abstract

The Marrow Niche Controls the Cancer Stem Cell Phenotype of Disseminated Prostate Cancer
Researchers showed that disseminated tumor cells (DTCs) recovered from marrow were significantly enriched for a cancer stem cells (CSCs) phenotype. Critically, the conversion of DTCs to CSCs is regulated by niche-derived GAS6 through the Mer/mTOR; molecules previously shown to regulate dormancy. [Oncotarget] Full Article

The Effect of F877L and T878A Mutations on Androgen Receptor Response to Enzalutamide
Researchers studied the effects of enzalutamide (Enza) on F877L and T878A mutants, as well as the double mutant androgen receptor (AR) (F877L/T878A). Molecular modeling revealed favorable structural changes in the double mutant AR that lead to a decrease in steric clashes for Enza. [Mol Cancer Ther] Abstract

Local Anesthetic Bupivacaine Induced Ovarian and Prostate Cancer Apoptotic Cell Death and Underlying Mechanisms In Vitro
Researchers investigated the effects of bupivacaine on ovarian and prostate cancer cell biology and the underlying molecular mechanisms. [Sci Rep] Full Article

Validation of Novel Biomarkers for Prostate Cancer Progression by the Combination of Bioinformatics, Clinical and Functional Studies
Only few predictive markers identified in silico have also been validated for clinical, functional or mechanistic relevance in disease progression. Scientists have used a broad, bioinformatics-based approach to identify such biomarkers across a spectrum of progression stages, including normal and tumor-adjacent, premalignant, primary and late stage lesions. [PLoS One] Full Article

Integrated and Functional Genomics Analysis Validates the Relevance of the Nuclear Variant ErbB380kDa in Prostate Cancer Progression
The nuclear localization of ErbB3 has been reported in various cancer tissues and cell lines but the nuclear functions and the putative correlation with tumor progression and resistance to therapy remain unclear. Researchers first assessed ErbB3 expression in normal and tumor prostate tissues. [PLoS One] Full Article


Phase II Trial of Weekly Docetaxel, Zoledronic Acid, and Celecoxib for Castration-Resistant Prostate Cancer
Investigators conducted a Phase II, open label, multinational prospective trial to evaluate the efficacy of weekly Docetaxel combined with Zoledronic acid and Celecoxib. [Invest New Drugs] Abstract

Free Sample: TeSR™2 Defined, Feeder-Free and Xeno-Free Human ES and iPS Cell Medium
Androgen Receptor Variant-Driven Prostate Cancer: Clinical Implications and Therapeutic Targeting
While there are myriad mechanisms of primary and acquired resistance to conventional and next-generation hormonal therapies in prostate cancer, the potential role of androgen receptor splice variants has recently gained momentum. [Prostate Cancer Prostatic Dis] Abstract

Visit our reviews page to see a complete list of reviews in the prostate cell research field.
NeoTract, Inc. Announces Data Showing Excellent Durability of Results for UroLift System at Four Years
NeoTract, Inc. announced the presentation of new clinical data from two high quality randomized studies of the company’s novel UroLift® System for patients with benign prostatic hyperplasia. [Press release from NeoTract, Inc. discussing research to be presented at the 2016 American Urological Association (AUA) Annual Meeting, San Diego] Press Release

From our sponsor:
Learn about mucociliary differentiation of primary bronchial epithelial cells.
Watch the video.
FDA Grants Profound Medical Corp. IDE Approval for TULSA-PRO™
Profound Medical Corp. announced that it has been granted Investigational Device Exemption approval from the U.S. Food and Drug Administration (FDA), for a multicenter Pivotal Clinical Trial. The objective of this trial is to evaluate the efficacy of the TULSA-PROTM System in patients with localized prostate cancer. [Profound Medical Corp. (GlobeNewswire, Inc.)] Press Release

Doctors Voice Optimism About Phase II Trial of ProscaVax in Mexico for Prostate Cancer
The trial of ProscaVax, OncBioMune’s novel cancer vaccine for prostate cancer, will be conducted in Mexico through a Joint Venture with Vitel Laboratorios S.A. de C.V. and is designed to evaluate the safety and efficacy of ProscaVax in PSA recurrent prostate cancer in hormone-naïve and hormone-independent patients. [OncBioMune Pharmaceuticals, Inc.] Press Release
National Institutes of Health (United States)

Food and Drug Administration (United States)

Center for Biologics Evaluation and Research (United States)

European Medicines Agency (European Union)

Medicines and Healthcare Products Regulatory Agency (United Kingdom)

Therapeutic Goods Administration (Australia)
NEW From Stem Cells to Human Development
September 25-28, 2016
Southbridge, Massachusetts

Visit our events page to see a complete list of events in the prostate cell community.
NEW Scientific Communications and Publishing Coordinator (STEMCELL Technologies Inc.)

NEW Research Associate – Prostate Cancer (University of Cambridge)

Research Technologist – Mammary and Prostate Stem Cell Biology (STEMCELL Technologies Inc.)

Postdoctoral Fellow – Cell Cycle Regulation in Prostate and Pancreatic Cancer (Purdue University)

Senior Scientist – Protein Analytics of Prostate and Other Cancer (Exosome Diagnostics)

Postdoctoral Fellow – Cancer Genomics (Henry Jackson Foundation)

Postdoctoral Fellow – Mechanisms of Castrate Resistance (University of Chicago)

Postdoctoral Research Fellow – Molecular Epidemiology of Cancer (Fred Hutchinson Cancer Research Center)

Postdoctoral Fellow – Genetic Determinants of Cancer (Memorial Sloan-Kettering Cancer Center)

Postdoctoral Fellow – Prostate Cancer (Cleveland Clinic)

Postdoctoral Fellow – Prostate Epithelial Homeostasis and Carcinogenesis (Baylor College of Medicine)

Recruit Top Talent: Reach potential candidates by posting your organization’s career opportunities on the Connexon Creative Job Board at no cost.

Have we missed an important article or publication in Prostate Cell News? Click here to submit!

Comments or suggestions? Submit your feedback here
Learn more about Prostate Cell News: Archives | Events | Contact Us